^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PGR positive

    i
    Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    5241
    Related biomarkers:
    Expression
    Mutation
    Others
    2d
    ETNA: Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer (ACTRN12613000119796)
    P3, N=632, Completed, Fondazione Michelangelo | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    |
    doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    3d
    Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer (clinicaltrials.gov)
    P4, N=75, Recruiting, Hebei Medical University Fourth Hospital | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Oct 2024 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Avastin (bevacizumab)
    3d
    Solitary adrenal metastasis presenting 15 years after breast cancer: a case report. (PubMed, Ann Med Surg (Lond))
    This case highlights that isolated adrenal metastasis can occur even after prolonged remission, with hypercalcemia as the sole presenting feature. It emphasizes the need for long-term surveillance in breast cancer survivors and the potential role of surgery in managing isolated adrenal metastases.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PGR positive
    6d
    Olaparib + Sapacitabine in BRCA Mutant Breast Cancer (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 positive • PGR positive
    |
    Lynparza (olaparib) • sapacitabine (CYC682)
    6d
    FLIM intensity-based image segmentation reveals upregulated energy metabolism and chemotherapy sensitivity in MCF-7 cells. (PubMed, J Cell Sci)
    Additionally, mitochondrial transfer enhances cancer cell sensitivity to oxidative stress-inducing anti-cancer drugs, suggesting a potential restoration of normal reactive oxygen species tolerance. Overall, FIBIS is a robust methodological approach that uses the phasor-FLIM technique to analyze NADH levels (free and bound) at the single-mitochondrion level, providing new biological insights into transferred mitochondrial dynamics in cancer cells.
    Journal
    |
    PGR (Progesterone receptor)
    |
    PGR positive
    18d
    PANSY: Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer (clinicaltrials.gov)
    P3, N=1560, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Jul 2021 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin
    23d
    Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • PGR positive
    |
    carboplatin • veliparib (ABT-888)
    23d
    HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Aug 2025 --> Dec 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    PGR positive
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • fulvestrant
    1m
    Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease (clinicaltrials.gov)
    P=N/A, N=42, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026 | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    1m
    Encapsulated papillary carcinoma with invasion in the breast: A case report with imaging findings. (PubMed, Radiol Case Rep)
    Postoperative recovery was uneventful, and she remained recurrence-free on tamoxifen therapy for 2 years. This case highlights key imaging features suggestive of invasion in EPC, which may facilitate preoperative assessment and management.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    tamoxifen
    1m
    A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    PGR (Progesterone receptor)
    |
    PGR positive
    |
    tamoxifen
    1m
    Advanced dual primary male breast cancer and lung cancer: A case report and literature review. (PubMed, Oncol Lett)
    Treatment consisted of neoadjuvant chemotherapy (epirubicin + carboplatin + trastuzumab + pertuzumab), a modified radical mastectomy with latissimus dorsi flap reconstruction and a thoracoscopic lung wedge resection. The therapeutic approach resulted in partial remission of the breast cancer prior to surgery and a stable disease status in the lung, with no recurrence at the 1-year follow-up. This case underscores the importance of comprehensive, integrative strategies and long-term follow-up for managing rare, complex cancer cases.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive • EGFR positive
    |
    Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • epirubicin